Kim Tsuchimoto Sells 4,090 Shares of Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 4,090 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the transaction, the director directly owned 7,396 shares of the company’s stock, valued at $823,840.44. This represents a 35.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

MNPR traded up $0.22 during trading on Thursday, reaching $113.94. The company’s stock had a trading volume of 142,825 shares, compared to its average volume of 220,179. Monopar Therapeutics Inc. has a 52-week low of $32.77 and a 52-week high of $124.82. The company’s fifty day moving average price is $104.63 and its 200-day moving average price is $74.34. The company has a market capitalization of $764.77 million, a price-to-earnings ratio of -52.51 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. Equities analysts predict that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MNPR. Janus Henderson Group PLC lifted its stake in Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after buying an additional 30,042 shares in the last quarter. RA Capital Management L.P. increased its position in Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after buying an additional 156,000 shares in the last quarter. Siren L.L.C. increased its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Monopar Therapeutics in the third quarter valued at $18,904,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on MNPR shares. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Morgan Stanley restated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. HC Wainwright increased their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Finally, Zacks Research cut shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Monopar Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.